News | December 21, 2012

Early Results Show Fewer Treatments, Higher Doses of Proton Therapy for Prostate Cancer Well Tolerated

Shorter course of treatment more convenient, cost-effective for patients

For men undergoing proton therapy for prostate cancer, fewer treatments with higher doses appear to be well tolerated, according to early clinical trial results. The trial, which continues to enroll patients, is evaluating using only 5 proton treatments given over 2 weeks for patients with low risk prostate cancer, a fraction of the 44 treatments typical in an 8-week standard course of therapy.

Patients who underwent the short-course of treatment reported no change in pre-treatment gastrointestinal, genitourinary or sexual function 6 months after completing therapy; no change in hormonal status was noted. The study reported on the outcomes of the first 22 who have completed treatment; more than 45 patients have now been enrolled on the protocol.

“This early analysis shows that short-course treatment is well tolerated, a result we continue to see in additional patients who we have enrolled in the trial and who have completed their therapy,” said Dr. William Hartsell, medical director of the CDH Proton Center, A ProCure Center, in Warrenville, Ill. “Being able to successfully treat patients in just a fraction of the time is not only convenient for patients, it also translates into substantial cost reductions.”

The study, which is led by Dr. Hartsell, is being conducted in the suburban Chicago center as well as the ProCure Proton Therapy Center in Oklahoma City. Ten patients were treated over 1 to 2 weeks at a higher dose for 5 treatments; another 12 patients were treated over 8 to 9 weeks with a standard proton dose and 44-day course of treatment. Prior to undergoing treatment and every 3 months following, side effects were monitored using industry-standard, patient-reported outcome measurements.

Data on the trial were presented at the Radiological Society of North America (RSNA) 98th Scientific Assembly and Annual Meeting.

Proton therapy for prostate cancer is clinically proven to be beneficial. Earlier this year, four studies, including one from ProCure, presented at the American Society for Radiation Oncology (ASTRO) annual meeting showed that proton therapy successfully reduces treatment related side effects and helps maintain a high quality of life for men with prostate cancer. The studies found little to no decline in genitourinary and gastrointestinal function for men treated with proton therapy and a faster return to pre-treatment function compared to standard X-ray radiation therapy.

“The body of research showing the benefits of proton therapy for prostate cancer is growing,” Hartsell said. “There is evidence that proton therapy results in fewer side effects compared to standard X-ray radiation therapy. With more research into shorter courses of treatment, we will continue to see the cost of the treatment come down while still maintaining the same quality of life patients have come to expect.”

For more information: www.procure.com/il

Related Content

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carri Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Feature | Henry Ford Hospital | May 21, 2019 | Dave Fornell, Editor
Henry Ford Hospital thought leaders regularly speak at the radiation oncology and radiology conferences about new res
Varian Acquiring Cancer Treatment Services International
News | Radiation Therapy | May 21, 2019
Varian Medical Systems announced it has entered into a definitive agreement to acquire India’s Cancer Treatment...
Videos | Radiation Therapy | May 21, 2019
This is a walk through of the ViewRay MRIdian MRI-guided radiotherapy system installed at ...
Partial Breast Irradiation Effective, Convenient Treatment Option for Low-Risk Breast Cancer
News | Radiation Therapy | May 20, 2019
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast...
New Method Improves Ability to Measure and Maximize Radiation Therapy Dose
News | Radiation Therapy | May 14, 2019
Delivering just the right dose of radiation for cancer patients is a delicate balance in their treatment regime....
Blue Earth Diagnostics Expands Access to Axumin in Europe
News | Radiopharmaceuticals and Tracers | May 13, 2019
Blue Earth Diagnostics announced expanded access to the Axumin (fluciclovine (18F)) imaging agent in Europe. The first...
Sponsored Content | Videos | Radiation Oncology | May 13, 2019
At ASTRO 2018, Accuray showcased new patient-fi
Radiotherapy After Chemo May Improve Survival in Advanced Hodgkin's Lymphoma Patients
News | Radiation Therapy | May 10, 2019
Patients with advanced Hodgkin's lymphoma who have large tumors at the time of diagnosis may benefit from radiotherapy...
IBA Partnering to Develop Advanced Digital Proton Therapy Technologies in Belgium
News | Proton Therapy | May 10, 2019
IBA (Ion Beam Applications SA) announced a research agreement with Skandionkliniken, Université Catholique de Louvain...